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Abstract: Delayed-enhanced dual-energy computed tomography (DECT) can evaluate the extent and
degree of myocardial fibrosis while coronary CT angiography (CCTA) is a widely accepted coronary
artery evaluation method. We sought to describe the role of combined cardiac CT for the evaluation
of underlying etiology in patients with newly diagnosed heart failure with reduced ejection fraction
(HFrEF). Sixty-three consecutive patients (31 men, 63 ± 16 years) with newly diagnosed HFrEF were
enrolled in this prospective study. Coronary artery disease and myocardial fibrosis were evaluated
on CCTA and DECT, respectively, and the tentative underlying etiologies of heart failure (HF) were
determined with combinations of findings from both CTs. Concordance between tentative etiologies
from cardiac CT and final etiologies from clinical decisions within a 2-year follow-up was assessed.
Eighteen patients were diagnosed with ischemic HF on initial cardiac CT, and the final diagnosis
was not changed. Another 45 patients with nonischemic HF included tentative etiologies of dilated
cardiomyopathy (n = 32, 71.1%), sarcoidosis or myocarditis (n = 8, 17.8%), amyloidosis (n = 2, 4.4%),
noncompaction (n = 2, 4.4%) and arrhythmogenic right ventricular cardiomyopathy (n = 1, 2.2%).
Five nonischemic HF patients showed different etiologies between initial cardiac CT and clinical
decisions. The concordance between cardiac CT and clinical decisions was 92.1%. A high degree of
concordance was achieved between tentative etiologies from cardiac CT and final diagnoses from
clinical decisions. Combined cardiac CT is a feasible, safe and effective imaging tool for the initial
evaluation of newly diagnosed HFrEF patients.
Keywords: heart failure with reduced ejection fraction; etiology; coronary computed tomographic
angiography; delayed-enhanced cardiac computed tomography
1. Introduction
Heart failure (HF) is a complex clinical condition that results from any structural or functional
impairment of ventricular filling or blood ejection and has increased in prevalence with significant
morbidity and mortality worldwide [1–4]. Early diagnosis and identification of the etiology behind HF
are crucial because some etiologies indicate specific treatments [5–8].
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In the past few years, multidetector computed tomography (CT) has been developed for
cardiovascular imaging, especially for the noninvasive evaluation of coronary artery disease (CAD) [9].
Because approximately two-thirds of HF patients have ischemic etiology, identifying the underlying
CAD is critical for HF management [10]. Therefore, cardiac CT can be considered a noninvasive imaging
tool for assessing the likelihood of CAD in HF [1,11]. In addition, prior studies showed that cardiac
CT can be used to evaluate myocardial fibrosis through myocardial delayed enhancement (MDE)
imaging in both myocardial infarction and nonischemic cardiomyopathy with similar contrast kinetics
for iodinated contrast agent and gadolinium [12–15]. Moreover, a recently developed dual-energy
technique could strengthen the role of cardiac CT in MDE evaluation as it improved image quality
with increased contrast-to-noise ratio through monochromatic imaging and iodine maps [16–18].
To determine the upstream pathophysiology and underlying etiology of newly diagnosed HF with
reduced ejection fraction (HFrEF), appropriate evaluation for both coronary arteries and myocardial
fibrosis is necessary [19]. Thus, we hypothesized that cardiac CT might be useful as a one-stop imaging
tool as it allows coronary arteries and myocardial fibrosis to be examined simultaneously. However,
there has been little research concerning this potential role of cardiac CT [20]. Therefore, we assessed
the feasibility, safety and effectiveness of applying cardiac CT to the evaluation of unknown underlying
etiology in newly diagnosed HFrEF through coronary CT angiography (CCTA) and delayed-enhanced
dual-energy CT (DECT). We compared tentative etiologies of HF from cardiac CT and final etiologies
of HF from two-year follow up clinical decisions.
2. Materials and Methods
2.1. Study Participants
From March 2014 to February 2015, we found 139 consecutive HF patients with the following
inclusion criteria: adult patients (≥20 years of age) who were newly diagnosed with HF with
relevant symptoms and signs, and with reduced left ventricular (LV) ejection fraction <40% on
echocardiography [21]. We excluded 62 patients with a clinically presumed definite etiology of HF
(47 patients for history of CAD, 8 for valvular heart disease, 3 for tachyarrhythmia, 2 for chemotherapy,
and 2 for congenital heart disease). Ten patients with cardiogenic shock and/or acute coronary
syndrome requiring urgent revascularization were excluded. Patients with decreased renal function of
serum creatinine >1.5 mg/dL (2 patients), or iodine contrast allergy (2 patients) were also excluded.
Finally, a total of 63 patients (31 men; mean age 62.6 ± 16.1 years, range 22–88 years, 47 inpatients and
16 outpatients) were enrolled. A flow diagram of enrolled study subjects and reasons for exclusion
are summarized in Figure S1. All study protocols were performed following the relevant guidelines.
The institutional review board and local ethics committee approved this prospective study and all
included study participants gave informed consent (1-2014-0047).
2.2. Cardiac CT
Cardiac CT was performed with a second-generation dual-source CT (Somatom Definition Flash;
Siemens Medical Solutions, Forchheim, Germany) within 3 or 4 days of initial HF diagnosis (Figure 1).
An oral ß-blocker was administered to patients with heart rates ≥65 bpm and sublingual nitroglycerin
was administered in all patients when there were no contraindications. For CCTA, a bolus of 1.0 mL/kg
iopamidol (370 mg/mL of iodine, Iopamiro 370, Bracco, Italy) was injected into an antecubital vein at a
flow rate of 5 mL/s followed by 40 mL of 40% blended iopamidol with saline and 20 mL of saline at
5 mL/s. The scan start was automatically initiated 5 s after reaching the threshold of 140 HU at the
descending aorta. After the CCTA scan, iopamidol was additionally injected to reach the final total
amount of 1.6 mL/kg in each patient followed by 20 mL of saline at 2 mL/sec. DECT was performed
12 min after the second injection. The scan range for the cardiac CT was from the carina to the
diaphragm, and the field of view was adjusted according to heart size. CCTA was performed with
the following parameters: prospective ECG-gated acquisitions at end-systole (heart rate > 65 bpm)
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or mid-diastole (heart rate ≤ 65 bpm), 120 reference kV and 250 reference mAs with Care kV and
CAREDose4D (Siemens Healthcare, Germany), a 512 × 512 pixel matrix, a 64 × 0.6 mm slice collimation,
and 0.33 sec rotation time. For CCTA, axial images were reconstructed using a slice thickness of 0.75 mm,
an increment interval of 0.5 mm, and a medium-smooth convolution kernel of iterative reconstruction
(I36f). Scanning parameters of DECT were as follows: retrospective ECG-gated acquisition with
tube current modulation and ECG pulsing window in 60–80% of the R-R interval, 100 kV and
138 effective mAs for the A tube, 140 kV and 162 effective mAs for the B tube, a 512 × 512 pixel
matrix, a 64 × 0.6 mm slice collimation and 0.33 sec rotation time. For DECT, the axial images were
reconstructed at the mid-diastolic phase using a 0.75 mm slice thickness, a 0.5 mm increment interval,
and a medium-smooth convolution kernel (D30f) at each tube voltage. CCTA images were transferred
to an off-line workstation (Aquaris 4.4.11, TeraRecon, San Francisco, CA) and images were reformatted
to the vertical and horizontal long axes, short axis, and curved multiplanar and volume rendering
images, in addition to the axial images. Axial images at each tube voltage from DECT were transferred
to a commercially available workstation (Syngo MMWP VE23A, Siemens Healthcare, Forchheim,
Germany). For MDE, 70-keV monochromatic images and gray-scale iodine maps were created to the
vertical long axis, horizontal long axis and short-axis planes with 8-mm slice thickness and no gap on
the workstation.
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Figure 1. Flow diagram for cardiac CT scanning. CCTA = coronary computed tomographic angiography;
DECT = dual-energy computed tomography.
We prospectively evaluated the safety of combined CT in both inpatients and outpatients including
the radiocontrast dye allergic reaction and contrast-induced acute kidney injury (CI-AKI). CI-AKI was
defined as an absolute increase in serum creatinine levels by ≥0.5 mg/dL or a relative increase in serum
creatinine by ≥50% from baseline observed within 72 h after contrast exposure. All enrolled patients
underwent blood analysis for renal function at 72 h after combined cardiac CT imaging.
2.3. Image Analysis
Two radiologists (8 and 10 years of experience in cardiac imaging, respectively), who were blinded
to each patient’s clinical findings, reviewed the CCTA and DECT images independently. On CCTA,
coronary arteries were evaluated with percent diameter stenosis; minimal (<25%), mild (25–49%),
moderate (50–69%) and severe (≥70%) [22]. Significant stenosis was defined with ≥50% diameter
reduction, and when multiple lesions existed in a given artery, the artery was classified by its worst
lesion. The final results were determined in consensus after assessment of interobserver agreements.
On DECT, MDE was visually defined with an obviously higher intensity within the myocardium at
the narrow window width and level (approximately 200 and 100 HU, respectively). The observers
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identified the presence of MDE and determined patients with infarction. MDE patterns were classified
as follows [23]: (1) midwall–enhancement at the portion of the myocardium located between the
endocardium and epicardium, (2) epicardial–enhancement of the outermost portion of the myocardium
beneath the pericardium, (3) patchy–spotty or nodular enhancement, (4) subendocardial–enhancement
at the innermost layer of the myocardium close to the ventricular cavity, or (5) transmural–enhancement
extending from the endocardium through to the epicardium. Infarction was defined as subendocardial
and transmural MDE corresponding to a perfusion territory of a coronary artery. If not the MDE
pattern for infarction, the nonischemic pattern was considered which spares the subendocardium or is
inconsistent with the perfusion territory of a coronary artery. Inconsistent cases were resolved in a
consensus reading and observers classified the patients into groups according to MDE pattern and
location (Figure 2).
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Finally, the observers considered the CCTA and DECT findings together to identify possible
etiologies of HF in consensus. Ischemic etiology was determined with the following criteria of prior
literature [24]: patients with severe stenosis at the left main or proximal left anterior descending
coronary artery; severe stenosis in two or more epicardial vessels, or infarction. For nonischemic
etiologies, the tentative etiologies of HF were determined according to groups defined by findings
from prior literature [25]. In addition, the observers considere ancillary findings of the myocardium,
such as myocardial low attenua <−10 HU [26] or p omi ent trabeculation, indicated by a thin,
compacted epi rdial layer a d a much thicker trabecular docardial layer [27]. The results of the
combined cardiac CT were revealed to the attending HF physicians to help the initial management
of newly diagnosed HFrEF patients. However, the tentative etiology determination of HF based on
combined cardiac CT findings was done independently.
2.4. Clinical Follow-Up
Each patient was followed for 2 years after an initial diagnosis of HF. Two cardiologists
independently reviewed the electronic medical records of each patient to collect all available clinical
test data, including results for electrocardiography, cardiac stress tests, echocardiography, conventional
coronary angiography (CAG), endomyocardial biopsy and cardiac magnetic resonance imaging (CMR)
during the study period. In addition, pertinent clinical history was also recorded for medical therapy
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and cardiac procedures such as revascularization of coronary arteries and cardiac surgery. Finally,
the final etiology of HF based on clinical follow-up was confirmed for each patient. To minimize the
possibility of bias from unblinded endpoint assessment, and to increase the accuracy of diagnosis,
etiology determination was done two years after combined cardiac CT evaluation.
2.5. Statistical Analysis
All statistical analyses were performed using statistical software (R program, version 3.5.0.;
R Foundation for Statistical Computing, Vienna, Austria). Continuous variables were presented with
mean values and standard deviations. Categorical variables were presented with the numbers of
patients. Inter-observer agreements for CAD evaluation, and for the detection and patterns of MDE,
were analyzed with kappa statics using contingency tables. The κ values were interpreted as follows:
0.00–0.20, slight agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80 good
agreement; and 0.81–1.00, excellent agreement. Concordance between tentative etiologies from cardiac
CT and final etiologies from clinical decisions was assessed with the Clopper-Pearson exact binomial
test with a null hypothesis probability of 0.8. There was no missing data in this study. In addition,
95% confidence intervals were calculated.
3. Results
3.1. Baseline Characteristics
The baseline characteristics of the study participants are summarized in Table 1. Combined
cardiac CT was performed successfully in all participants. The mean heart rate during cardiac CT was
74.3 ± 12.8 bpm. The effective radiation dose of CT was calculated using a cardiac-specific conversion
factor: dose-length product x 0.014 mSv/(mGy·cm) [28], and the mean value was 1.22 ± 0.74 mSv for
CCTA and 5.32 ± 1.85 mSv for DECT.
Table 1. Baseline characteristics of the study population.
Age 62.6 ± 16.1
Male gender 31 (49.2%)
BMI, kg/m2 24.1 ± 5.0
Inpatient: Outpatient 47 (74.6%): 16 (25.4%)
NYHA class
Class I 4 (6.3%)
Class II 40 (63.5%)
Class III 17 (27.0%)
Class IV 2 (3.2%)
Laboratory findings
White blood cell (×103/µL) 7.1 ± 2.1
Hemoglobin (g/dL) 13.5 ± 2.47
Albumin (g/dL) 3.8 ± 0.6
Cholesterol (mg/dL) 149.6 ± 36.9
Sodium (mmol/L) 140.1 ± 2.6
eGFR (mL/min/1.73 m2) 86.7 ± 16.8
Creatinine (mg/dL) 0.8 ± 0.2
NT-proBNP (pg/mL) 4802.4 ± 6124.1
Clinical history
Hypertension 32 (50.8%)
Diabetes mellitus 23 (36.5%)
Dyslipidemia 8 (12.7%)
Current/ex-smoker 13 (20.6%)/8 (12.7%)
Alcohol 16 (25.4%)
Echocardiography findings
LVEDD, mm 64.3 ± 6.7
LVEF, % 28.3 ± 8.2
Fractional shortening, % 21.8 ± 12.6
Values are n (%) or mean ± SD. BMI = body mass index, NYHA = New York Heart Association, eGFR = estimated
glomerular filtration rate, NT-proBNP = n-terminal of the prohormone brain natriuretic peptide, LVEDD = left
ventricular end-diastolic diameter, LVEF = left ventricular ejection fraction.
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3.2. Safety of Combined CT
We prospectively evaluated the safety of combined CT in both inpatients and outpatients. Among
63 patients there was no radiocontrast dye allergic reaction. Regarding the prevention of CI-AKI,
intravenous normal saline hydration was done for all hospitalized inpatients depending on effective
circulating volume status, while oral hydration was only encouraged for outpatients. When CI-AKI
was defined as an absolute increase in serum creatinine levels by ≥0.5 mg/dL, or a relative increase
in serum creatinine by ≥50% from baseline is observed within 72 h after contrast exposure, only two
patients (3.2%) showed CI-AKI. However, their renal function was recovered spontaneously without
any further intervention. There was no contrast-related urgent hemodialysis or death during the
study period.
3.3. Cardiac CT Findings
On CCTA, the two radiologists independently identified significant CAD with excellent
inter-observer agreement (κ = 0.806) (Table 2). Afterwards, the observers determined significant CAD
in 20 patients in consensus (31.7%, 20/63); 1-vessel disease in seven patients, 2-vessel disease in seven
patients, and 3-vessel disease in six patients.
Table 2. Inter-observer agreement for main findings on cardiac CT.
Observer 1 Observer 2 Kappa
CAD No significant CAD 43 44
0.806
1-vessel disease 6 7
2-vessel disease 8 6
3-vessel disease 6 6
MDE No 21 22
0.806Infarction 15 16
Non-ischemic 27 25
CAD = coronary artery disease, MDE = myocardial delayed enhancement.
On DECT, inter-observer agreement was excellent for assessment (κ = 0.806) (Table 2). Afterwards,
the observers concluded that MDE was observed in 41 patients (65.1%, 41/63), with infarction in
15 patients (23.8%, 15/63) and nonischemic patterns in 26 patients (41.3%, 26/63) in a consensus
reading. Twenty-two patients showed no MDE (Group I). For the 15 patients with infarction (Group II),
nine patients demonstrated multifocal subendocardial and transmural MDE at multi-vessel territories,
five showed subendocardial or transmural MDE at the left anterior descending coronary artery territory,
and one showed transmural MDE at the right coronary artery territory. For the nonischemic patterns,
seven patients showed midwall MDE at the basal septum, four showed patchy MDE at basal junctions
and three showed both patterns (Group III). In addition, 10 patients showed multifocal epicardial
and/or patchy MDE (Group IV), and two showed global subendocardial MDE (Group V).
3.4. Tentative Etiologies of HF from Cardiac CT
The main results of tentative etiologies are described in Figure 2. All 15 patients with infarction
on DECT (Group II) were diagnosed as ischemic HF according to the criteria and showed significant
CAD on CCTA; 1-vessel disease in four patients, 2-vessel disease in five patients, and 3-vessel disease
in six patients. For these patients, infarctions were observed at the corresponding vascular territories.
Additionally, three patients of Group I were regarded as ischemic HF because one patient showed
1-vessel disease with severe stenosis at the left anterior descending coronary artery and two patients
showed 2-vessel disease with severe stenosis at the left anterior descending coronary artery and right
coronary artery on CCTA.
Eighteen patients of Group I and 14 patients of Group III had dilated cardiomyopathy. One patient
of Group I showed significant 1-vessel disease on CCTA but was not regarded as ischemic HF because
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the diseased vessel was in the left circumflex artery without perfusion defect. Other patients with
tentative diagnosis of dilated cardiomyopathy did not show significant CAD on CCTA. Eight patients
of Group IV were supposed as having sarcoidosis or myocarditis without significant CAD on CCTA.
One patient of Group IV was diagnosed with arrhythmogenic right ventricular cardiomyopathy
because of multifocal low attenuations which did not correspond to the vascular territory at both
ventricles on cardiac CT. One patient of Group I and one patient of Group IV were diagnosed as
isolated LV noncompaction with prominent trabeculations according to the diagnostic criteria of
non-compacted-to-compacted thickness ratio >2.3 [27]. For two patients of Group V, amyloidosis
was considered. Although one patient with presumed amyloidosis had significant 1-vessel disease
on CCTA, ischemic HF was not considered because of moderate stenosis in the left circumflex artery.
Representative cases of nonischemic HF are shown in Figure 3.
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3.5. Final Etiologies of HF from Clinical Decisions and Concordance Between Tentative and Final Etiologies
Details of the results from clinical follow-up are described in the Supplemental materials.
Of 18 patients with ischemic HF from cardiac CT, 16 patients underwent CAG and significant CAD
was confirmed. In Group II, two patients refused to undergo CAG and were diagnosed as ischemic HF
based on CMR findings with myocardial infarction. One representative case of ischemic HF is shown
in Figure 4.
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i r 4. Representative case of ischemic heart failure. On coro ary CT ngiography (A), total occlusion
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(bla k open arrows) (D).
o g 32 atie ts it a te tative iag osis of ilate car io yo at y, 26 atie ts er e t
. f t e , o e atie t of ro I as e ly iag ose as o co actio it [27].
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ocarditis [30] according to each diagnostic criterion. The other three patients were finally regarde as
unspecified cardiomyopathy and one patient as arrhythmogenic right ventricular cardiomy pathy [31].
CMR and clinical findings finally concluded in the same diagnosis for a patient with a te tati e
ia osis of arrhythmogenic right ventricular cardiomyopathy [31]. Patients with a tentative diagnosis
of LV non-compaction showed consistent findings on CMR as well [32]. T o patients with a tentative
diagnosis of amyloidosis were pathologically c nfirmed with cardiac biopsy.
o su ari e, fi e patie ts f t e 63 stu y partici ts s e iffere t eti l ies f r r
et ee c r i c cli ic l f ll - ( i re ). c r ce et ee te t ti e i ses
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i r t t r fere ce val e of 0.8 (p . ).
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4. Discussion
The principal finding of this proof-of-concept study was that a relatively high degree of concordance
was achieved between tentative etiologies from cardiac CT and final diagnoses from clinical decisions
for the evaluation of underlying etiologies of HFrEF, even after exclusion of patients with a clinically
presumed definite ti l gy of HF including history f CAD, valvular he rt d s ase, tachyarrhythmia,
chemotherapy and congenital heart disease. Combined cardiac CT, which ca evaluate the coronary
anatomy and myocardial fibrosis comprehensively, is a feasible, effective and safe imaging tool in the
initial etiology evaluation of newly diagnosed HFrEF patients.
Once a HF diagnosis i establish d, the next process is determining its etiology. To do this,
we need to narrow down the potential causes of newly diagnosed HF by examining the possibility of
CAD [10]. Hence, cardiac CT could be recommended to exclude significant CAD in patients with low to
intermediate pre-test probabilities of CAD, or those with equivocal stress tests, to minimize unnecessary
invasive pr cedures during the HFrEF etiology work up [1,11]. In the curr nt study, 31.7% (20/63) of
the patients had newly diagnosed significant CAD on CCTA. Because most patients with longstanding
ischemic cardiomyopathy usually have evidence of prior or recent myocardial infarction, nonischemic
cardiomyopathy might be suggested in patients who do not show MDE [19]. However, we found five
patients in Group I (22.7%, 5/22) with ewly diagnosed significant CAD without infarction. Because
significant CAD and nonischemic HF are not mutually exclusive, simultaneous assessment of coronary
arteries and myocardial disease is needed to comprehensively evaluate HF etiologies. The presence of
CAD represents a potentially treatable cause of HF while also being synergistically and independently
associated with worse long-term outcomes. CAD per se would be important in the treatment of newly
diagnosed HF [33].
The locations and patterns of MDE on CMR are often distinct, so a pattern-based approach for MDE
might provide useful diagnostic information on the underlying myocardial disease in HF [25]. Although
previous studies have steadily demonstrated that cardiac CT showed promise in MDE assessment
compared to CMR, most studies focused on the evaluation of MDE itself, such as enhancement
pattern and location, extent of infarction or fibrosis quantification [12–15]. Therefore, we tried to
focus on the utility of cardiac CT for the evaluation of underlying etiologies in newly diagnosed HF
through MDE imaging in addition to coronary artery evaluation. In the current study, we found
that five patients showed discordant results between cardiac CT and clinical follow-up, and four of
them belonged to Group IV with multifocal epicardial and patchy MDE. Dilated cardiomyopathy
J. Clin. Med. 2020, 9, 2270 10 of 12
should be considered primarily for Group I (no MDE) or III (mid-wall MDE at basal septum or patchy
MDE at basal junctions), whereas various less common myocardial diseases would be considered for
Group IV. Because we determined a specific myocardial disease based on MDE alone for our study,
the concordance between tentative etiology and final decision for the patients in Group IV might be
low. Therefore, clinical features should be considered when determining a specific cause of HF in real
practice. We would expect the clinical value of cardiac CT with MDE to increase with an analysis of
clinical features in HF. Although we focused on coronary arteries and MDE imaging with cardiac CT in
the current study, cardiac CT also provides reliable information on cardiac structure, cardiac function,
cardiac venous anatomy and the pulmonary venous system, which are all considered important in
HF management [34]. While cardiac CT has limitations concerning radiation exposure and iodinated
contrast agents, it has several strong advantages over CMR, as whole myocardial coverage is possible
with shorter times and as it is more readily available to patients. Additionally, cardiac CT can be an
important alternative to CMR in patients with claustrophobia or CMR-unsafe devices.
The present study has several limitations. First, a relatively small number of patients was included in
this proof of concept study. The ratio of ischemic versus nonischemic HF in the current study was different
from the real world because we excluded patients with a known clinical cardiovascular history, especially
those with known CAD. In addition, most patients were diagnosed as dilated cardiomyopathy (49.2%,
31/63), probably idiopathic, and ischemic HF (28.6%, 18/63), with other cardiomyopathies making up only
a small portion of the study participants. This might have resulted in the high degree of concordance seen
in our study. Second, not all patients underwent CAG, especially those with no significant CAD on CCTA.
This finding might be due to the well-known high negative predictive value of CCTA in the evaluation of
CAD. Third, the cardiac CT protocol should be modified before it can be applied to daily clinical practice.
Because our scanner previously did not permit prospective ECG-gated acquisition with the dual-energy
technique, we performed retrospective ECG-gated acquisition for DECT. However, prospective ECG
gating reduces radiation exposure and now it is possible to do so with the dual-energy technique. Fourth,
performing cardiac CT might increase iodinated contrast agent loads and radiation exposure in patients
who have compelling indication for invasive coronary angiography. For those high-risk patients, risk and
benefit should be fully discussed in advance.
5. Conclusions
To determine the upstream pathophysiology and underlying etiology of newly diagnosed HFrEF,
appropriate evaluation for both coronary arteries and myocardial fibrosis is necessary. Combined
cardiac CT could be a useful one-stop-imaging tool for comprehensive evaluation of underlying
etiologies by making it possible to evaluate coronary anatomy and myocardial fibrosis simultaneously.
Combined cardiac CT is a feasible, safe and effective imaging tool in the initial etiology evaluation for
newly diagnosed HFrEF patients.
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